Journal of SAFOMS

Register      Login

VOLUME 6 , ISSUE 1 ( January-June, 2018 ) > List of Articles


Human Papillomavirus and its Testing

Citation Information : Human Papillomavirus and its Testing. J South Asian Feder Menopause Soc 2018; 6 (1):0-0.

DOI: 10.5005/jp-jsafoms-6-1-iv

Published Online: 01-06-2018

Copyright Statement:  Copyright © 2018; Jaypee Brothers Medical Publishers (P) Ltd.


PDF Share
  1. Ebrahim SH, McKenna MT, Marks JS. Sexual behavior: related adverse health burden in the United States. Sex Transm Infect 2005 Jan;81:38-40.
  2. Burchell AN, Richardson H, Mahmud SM, Trottier H, Tellier PP, Hanley J, Coutlée F, Franco EL. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer stimulation and empirical data from a cohort study of young women in Montréal, Canada. Am J Epidemiol 2006 Mar;163(6):534-543.
  3. Veldhuijzen NJ, Snijders PJ, Reiss P, Meijer CJ, van de Wijgert JH. Factors affecting transmission of mucosal human papilloma virus. Lancet Infect Dis 2010 Dec;10(12):862-874.
  4. Munoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006 Aug;24 (Suppl 3):S3/1-10.
  5. Braaten KP, Laufer MR. Human Papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol 2008 Winter; 1(1):2-10.
  6. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010 May;401(1):70-79.
  7. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ. International Agency for Research on Cancer: Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003 Feb;348(6):518-527.
  8. Lowy DR, Schiller JT. Reducing HPV-associated cancer globally. Cancer Prev Res (Phila) 2012 Jan;5(1):18-23.
  9. Centers for Disease Control and Prevention. Human papillomavirus-associated cancers—United States, 2004-2008. MMWR 2012 Apr;61(15):258-261.
  10. Castellsagué X, de Sanjose S, Aguado T, Louie KS, Bruni L, Munoz J, Diaz M, Irwin K, Gacic M, Beauvais O, et al. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). HPV and cervical cancer in the world [Report]. Geneva, Barcelona: WHO, ICO; 2007.
  11. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010 Dec;127(12):2893-2917.
  12. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle P. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011 Mar;103(5):368-383.
  13. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007 Sep;370(9590):890-907.
  14. Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003;31:14-19.
  15. Barnholtz- Sloan J, Patel N, Rollison D, Kortepeter K, MacKinnon J, Giuliano A. Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control 2009 Sep;20(7):1129-1138.
  16. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population-based case-control study of prospectively recorded data. BMJ 2009 Jul;339:b2968.
  17. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006 Aug;24(Suppl 3):S3/78-89.
  18. Moyer VA.; US Preventive Services Task Force. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2012 Jun;156(12):880-891.
  19. Kulasingam SL, Havrilesky L, Ghebre R, Myers ER. Screening for cervical cancer: a decision analysis for the US Preventive Services Task Force. AHRQ Publication No. 11-05157-EF-1. Rockville (MD): Agency for Healthcare Research and Quality; 2011.
  20. Joste N, Gober-Wilcox J. The modern cytology laboratory: moving beyond the Pap test. Obstet Gynecol Clin North Am 2013 Jun;40(2):199-210.
  21. Cervix cancer screening. IARC handbook of cancer prevention. Vol. 10. Lyons: IARC Press; 2005.
  22. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009 Apr;360(14):1385-1394.
  23. de Kok IM, van Rosmalen J, Dillner J, Sasieni P, Iftner T, van Ballegooijen M. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost-effectiveness analysis based on a Dutch microsimulation model. BMJ 2012 Mar;344:e670.
  24. Ferlay J, Shin HR, Bray F, Mathers C, Parkin DM. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC Cancer Base No. 10. Lyon: International Agency for Research on Cancer; 2010.
  25. Kitchener HC, Castle PE, Cox JT. Chapter 7: achievements and limitations of cervical cytology screening. Vaccine 2006 Aug;24 (Suppl 3):S3/63-S3/70.
  26. Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, Weigl B, Zhang WH, Peck RB, Li L, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008 Oct;9(10):929-936.
  27. Belinson JL, Du H, Yang B, Wu R, Belinson SE, Qu X, Pretorius RG, Yi X, Castle PE. Improves sensitivity of vaginal self-collection and high-risk human papillomavirus testing. Int J Cancer 2012 Apr;130(8):1855-1860.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.